Efficacy and safety of tivozanib in recurrent, platinum-resi
Tivozanib is a potent selective pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor with a long half-life.

This study assessed its activity in patients with a recurrent, platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer (OC).

Eligible patients had recurrent, platinum-resistant OC and measurable or detectable disease. There was no limit on the number of prior regimens. Treatment consisted of tivozanib 1.5 mg orally once daily for 21 days in a 28-day cycle. The primary endpoint was the objective response rate (ORR). Secondary endpoints were progression-free survival (PFS), overall survival (OS), and toxicity assessment. Thirty-one patients were enrolled, and 30 were treated.

- Twenty-four patients were evaluable for response, and four achieved a partial response.

- An additional fourteen patients had stable disease (SD). The clinical benefit rate (PR + SD) was 75.0%, and the median duration of objective response was 5.7 months.

- For all patients on trial, the median PFS was 4.1 months and OS 8.6 months.

- There were no treatment-related deaths. Serious adverse events occurred in 13.3% of patients and included small intestinal perforation or obstruction and stroke. Grade 3–4 adverse events occurred in 60% of patients, including hypertension and fatigue.

In conclusion, Tivozanib is effective in patients with recurrent OC, with moderate toxicity and no treatment-related deaths, supporting its further development.

Gynecologic Oncology
Source: https://doi.org/10.1016/j.ygyno.2021.08.005